Home
Conditions
Pathologic Complete Response

Clinical trial condition

Pathologic Complete Response

Explore clinical trials studying Pathologic Complete Response. Study availability and eligibility vary by location and protocol.

98 public trials 32 recruiting studies

Refine in advanced search Browse all conditions

Pathologic Complete Response trial results

Recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995

Conditions: Androgen Deprivation Therapy, Disease Attributes, Disease Progression, +7 more
Locations: Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC) Oklahoma City, Oklahoma, United States

View Trial Details

Recruiting

Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma

NCT07430579

Conditions: Disease Attributes, Disease Progression, Immune-Related Adverse Events, +6 more
Locations: The Second Qilu Hospital of Shandong University Jinan, China

View Trial Details

Recruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT04055220

Conditions: Angiosarcoma, Behavior, Bone Diseases, +31 more
Locations: Hôpital Jean Minjoz Besançon, France

Institut Bergonié Bordeaux, France

Centre Oscar Lambret Lille, France

Centre Léon Bérard Lyon, France

View all 16 locations

View Trial Details

Recruiting

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

NCT07353723

Conditions: Disease Attributes, Disease Progression, Head & Neck Cancer, +6 more
Locations: Tangdu Hospital, Air Force Medical University, Xi'an 710038, Shaanxi Province, China Shanxi, Province, China

View Trial Details

Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

NCT07353840

Conditions: Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, +14 more
Locations: Shanghai General Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

NCT07328854

Conditions: Carcinoma, Disease Attributes, Disease Progression, +16 more
Locations: Anhui Provincial Cancer Hospital Hefei, Anhui, China

Fujian Cancer Hospital Fuzhou, Fujian, China

Sun Yat-sen University cancer center Guangzhou, Guangdong, China

the Affiliated Cancer Hospital of Guangzhou Medical University Guangzhou, Guangdong, China

View all 15 locations

View Trial Details

Recruiting

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

NCT07328841

Conditions: Carcinoma, Disease Attributes, Disease Progression, +17 more
Locations: The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China

Cancer Center of Guangzhou Medical University Guangzhou, Guangdong, China

Sun Yat-sen University cancer center Guangzhou, Guangdong, China

The Second Affiliated Hospital of Sun Yat-sen University (SYSU) Guangzhou, Guangdong, China

View Trial Details

Recruiting

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

NCT06364371

Conditions: Disease Attributes, Disease Progression, Pathologic Complete Response, +3 more
Locations: The Sixth Affiliated Hospital, Sun Yatsen University Guangzhou, Guangdong, China

View Trial Details

Recruiting

Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer

NCT07166185

Conditions: Breast Diseases, Breast Neoplasms, Disease Attributes, +9 more
Locations: Medical oncology department - Anti Cancer Center of Blida Blida, Algeria

View Trial Details

Recruiting

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

NCT06811844

Conditions: Chemotherapy, Complete Response, Disease Attributes, +16 more
Locations: The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China

Zhangzhou Affiliated Hospital of Fujian Medical University Zhangzhou, Fujian, China

Hainan General Hospital Haikou, Hainan, China

View Trial Details

Pathologic Complete Response

Pathologic Complete Response trial results

Related conditions